We are international
Donate
• about myeloma TEXT SIZE   
get the correct diagnosis    back

ASH 2011: Dr. Mateos - Smoldering Multiple Myeloma (SMM) At High-Risk of Progression to Symptomatic Disease: A Phase III, Randomized, Multicenter Trial Based On Lenalidomide-Dexamethasone (Len-Dex) As Induction Therapy Followed by Maintenance Therapy with Len Alone Vs No Treatment
María-Victoria Mateos, MD, PhD
Hospital Clinico Universitario
Salamanca, Spain
12.06.11


To view the video full screen, click on the small button next to the volume control in the lower right hand corner.


 related articles
Insights into Smoldering (Asymptomatic) Multiple Myeloma
What is Smoldering Myeloma?
ASH 2011: Dr. Mateos - Smoldering Multiple Myeloma (SMM) At High-Risk of Progression to Symptomatic Disease: A Phase III, Randomized, Multicenter Trial Based On Lenalidomide-Dexamethasone (Len-Dex) As Induction Therapy Followed by Maintenance Therapy with Len Alone Vs No Treatment
High-Risk Smoldering Myeloma Addressed by Group 1 during Second Annual International Myeloma Working Group Summit


You might also be interested in:

Insights into Smoldering (Asymptomatic) Multiple Myeloma
An ASCO Connection Current Controversies in Oncology article featuring Dr. Kyle of the Mayo Clinic.

What is Smoldering Myeloma?
Dr. Ola Landgren
National Cancer Institute
Bethesda, Maryland

ASH 2011: Dr. Mateos - Smoldering Multiple Myeloma (SMM) At High-Risk of Progression to Symptomatic Disease: A Phase III, Randomized, Multicenter Trial Based On Lenalidomide-Dexamethasone (Len-Dex) As Induction Therapy Followed by Maintenance Therapy with Len Alone Vs No Treatment
María-Victoria Mateos, MD, PhD
Hospital Clinico Universitario
Salamanca, Spain

High-Risk Smoldering Myeloma Addressed by Group 1 during Second Annual International Myeloma Working Group Summit
How to maximize benefits of early treatment for patients with high-risk smoldering myeloma, yet avoid unnecessary treatment and toxicities.